Engineered immune cells take aim at Hard-to-Treat myeloma
⭐️ CURE ⭐️
Not yet recruiting
This trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three pr…
Phase: PHASE1, PHASE2 • Sponsor: UCARsgen Biotech Limited • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC